ATHE
Alterity Therapeutics Ltd.
NASDAQ · Healthcare · Biotechnology · AU
$2.43
−7.25%Year over year
Reported trailing growth
- Revenue
- -100.0%
- EBITDA
- -94.8%
- EBIT
- -94.8%
- EPS
- -4.8%
- Free cash flow
- +100.0%
- Operating cash flow
- —
Forward estimates
Based on analyst estimates
- Revenue
- —
- EBITDA
- —
- EPS
- +92.6%
Three-year CAGR
- Revenue
- -100.0%
- EBITDA
- -90.7%
- EBIT
- -90.7%
- Net income
- -88.4%
- EPS
- -15.8%
- Free cash flow
- +100.0%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026